The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders

References

• Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004b;4(5):349–360.
   PubMed Web of Science ®Google Scholar
• Adams J. Development of the proteasome inhibitor PS-341. Oncologist. 2002;7:9–16.
   PubMed Web of Science ®Google Scholar
• Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 2004a;5:417–421.
   PubMed Web of Science ®Google Scholar
• Nussbaum AK, Dick TP, Keilholz W, et al. Cleavage motifs of the yeast 20S proteasome B subunit deduced from digests of enolase 1. Proc Natl Acad Sci. 1998;95:12504–12509.
   PubMed Web of Science ®Google Scholar
• Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia. 2002;16:433–443.
   PubMed Web of Science ®Google Scholar
• Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci U S A. 2000;97(8):3850–3855.
   PubMed Web of Science ®Google Scholar
• Karin M, Cao Y, Greten FR, et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2(4):301–310.
   PubMed Web of Science ®Google Scholar
• Zhang HG, Wang J, Yang X, et al. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene. 2004;23(11):2009–2015.
   Google Scholar
• Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res. 2001;7:1419–1428.
   PubMed Web of Science ®Google Scholar
• Lee AH, Iwakoshi NN, Anderson KC, et al. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A. 2003;100(17):9946–9951.
   PubMed Web of Science ®Google Scholar
• Wang C, Cusack JC, Liu R, et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Am. 1999;5(4):412–417.
   Web of Science ®Google Scholar
• Kordes U, Krappmann D, Heissmeyer V, et al. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia. 2000;14(3):399–402.
   PubMed Web of Science ®Google Scholar
• Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98(8):2301–2307.
   PubMed Web of Science ®Google Scholar
• Ni H, Ergin M, Huang Q, et al. Analysis of expression of nuclear factor κB (NF-κB) in multiple myeloma: downregulation of NF-κB induces apoptosis. Br J Hematol. 2001;115:279–286.
   PubMed Web of Science ®Google Scholar
• Brown CJ, Lain S, Verma CS, et al. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009;9(12):862–873.
   PubMed Web of Science ®Google Scholar
• An WG, Hwang SG, Trepel JB, et al. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia. 2000;14(7):1276–1283.
   PubMed Web of Science ®Google Scholar
• Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology. 2004;18(14 Suppl 11):14–21.
   PubMedGoogle Scholar
• Velcade [package insert]. Cambridge (MA): Millenium Pharmaceuticals; 2003.
   Google Scholar
• Bross PF, Kane R, Farrell AT, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res. 2004;10:3954–3964.
   PubMed Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–440.
   PubMed Web of Science ®Google Scholar
• Eriksson E, Zaman F, Chrysis D, et al. Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice. PLoS One. 2012;7(11):e50523.
   PubMed Web of Science ®Google Scholar
• Hou M, Eriksson E, Svechnikov K, et al. Bortezomib treatment causes long-term testicular dysfunction in young male mice. Mol Cancer. 2014;13:155.
   PubMed Web of Science ®Google Scholar
• Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, et al. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun. 1995;217(3):1070–1077.
   PubMed Web of Science ®Google Scholar
• Shinohara K, Tomioka M, Nakano H, et al. Apoptosis induction resulting from proteasome inhibition. Biochem J. 1996;317 (Pt 2):385–388.
   PubMed Web of Science ®Google Scholar
• Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res. 2002;62:1083–1086.
   Google Scholar
• Masdehors P, Merle-Béral H, Maloum K, et al. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood. 2000;96(1):269–274.
   PubMed Web of Science ®Google Scholar
• Delic J, Masdehors P, Omura S, et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis. Br J Cancer. 1998;77(7):1103–1107.
   PubMed Web of Science ®Google Scholar
• Cusack JC, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res. 2001;61:3535–3540.
   PubMed Web of Science ®Google Scholar
• Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9:1136–1144.
   PubMed Web of Science ®Google Scholar
• Horton TM, Gannavarapu A, Blaney SM, et al. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006;58(1):13–23.
   PubMed Web of Science ®Google Scholar
• Minderman H, Zhou Y, O’Loughlin KL, et al. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemother Pharmacol. 2007;60(2):245–255.
   PubMed Web of Science ®Google Scholar
• Junk S, Cario G, Wittner N, et al. Bortezomib treatment can overcome glucocorticoid resistance in childhood B-cell precursor acute lymphoblastic leukemia cell lines. Klin Padiatr. 2015;227(3):123–130.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang X, Li Y, et al. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway. Pharmazie. 2012;67(2):187–192.
   PubMed Web of Science ®Google Scholar
• Kurkland JF, Meyn RE. Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells. Int J Cancer. 2001;96:327–333.
   PubMed Web of Science ®Google Scholar
• Russo SM, Tepper JE, Baldwin AS, et al. Enhancement of radiosensitivity by proteasome inhibition: implicaitons for a role of NF-κB. Int J Radiation Oncology Biol Phys. 2001;50(1):183–193.
   PubMed Web of Science ®Google Scholar
• LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62:4996–5000.
   PubMed Web of Science ®Google Scholar
• Nawrocki ST, Bruns CJ, Harbison MT, et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther. 2002;1:1243–1253.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20(22):4420–4427.
   PubMed Web of Science ®Google Scholar
• Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004;22(11):2108–2121.
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002;8:2505–2511.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005;105(8):3058–3065.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165–172.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson JR, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26):2609–2617.
   PubMed Web of Science ®Google Scholar
• Kane RC, Bross PF, Farrell AT, et al. Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8:508–513.
   PubMed Web of Science ®Google Scholar
• Richardson P, Hideshima T, Mitsiades C, et al. Proteasome inhibition in hematologic malignancies. Ann Med. 2004;36(4):304–314.
   PubMed Web of Science ®Google Scholar
• Kane RC, Farrell AT, Sridhara R, et al. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res. 2006;12(10):2955–2960.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110(10):3557–3560.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. Leukemia. 2008;359(9):906–917.
   Google Scholar
• Teicher BA, Anderson KC. CCR 20th Anniversary Commentary: in the beginning, there was PS-341. Clin Cancer Res. 2015;21(5):939–941.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Goldschmidt H, Rosinol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013;31(26):3279–3287.
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28(30):4621–4629.
   PubMed Web of Science ®Google Scholar
• Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376(9758):2075–2085.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schmidt-Wolf IG, Van Der Holt B. et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012;30(24):2946–2955.
   PubMed Web of Science ®Google Scholar
• Rosinol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120(8):1589–1596.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23):4745–4753.
   PubMed Web of Science ®Google Scholar
• Totani H, Ri M, Kato C, et al. Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma. Int J Hematol. 2016;103(3):316–321.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23(4):676–684.
   PubMed Web of Science ®Google Scholar
• Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20(3):520–525.
   PubMed Web of Science ®Google Scholar
• Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23(4):667–675.
   PubMed Web of Science ®Google Scholar
• Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol. 2006;24(13):2105–2112.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24(30):4867–4874.
   PubMed Web of Science ®Google Scholar
• Mato AR, Feldman T, Goy A. Proteasome inhibition and combination therapy for non-Hogkin’s lymphoma: from bench to bedside. Oncologist. 2012;17:694–707.
   PubMed Web of Science ®Google Scholar
• Cortes J, Thomas D, Koller C, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 2004;10:3371–3376.
   PubMed Web of Science ®Google Scholar
• Attar EC, De Angelo DJ, Supko JG, et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res. 2008;14(5):1446–1454.
   PubMed Web of Science ®Google Scholar
• Attar EC, Johnson JL, Amrein PC, et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013;31(7):923–929.
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:37–45.
   PubMed Web of Science ®Google Scholar
• Blaney SM, Bernstein M, Neville K, et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children’s Oncology Group study (ADVL0015). J Clin Oncol. 2004;22(23):4804–4809.
   PubMed Web of Science ®Google Scholar
• Horton TM, Pati D, Plon SE, et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children’s Oncology Group study. Clin Cancer Res. 2007;13(5):1516–1522.
   PubMed Web of Science ®Google Scholar
• Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010;55(2):254–259.
   PubMed Web of Science ®Google Scholar
• Messinger YH, Gaynon PS, Sposto R, et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood. 2012;120(2):285–290.
   PubMed Web of Science ®Google Scholar
• Horton TM, Lu X, O’Brien MM, et al. Bortezomib reinduction therapy to improve response rates in pediatric ALL in first relapse: a Children’s Oncology Group (COG) study (AALL07P1) [abstract]. J Clin Oncol. 2013;31:10003.
   Google Scholar
• Horton TM, Perentesis JP, Gamis AS, et al. A phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2014;61(10):1754–1760.
   PubMed Web of Science ®Google Scholar
• Horton TM, Drachtman RA, Chen L, et al. A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children’s Oncology Group study. Br J Haematol. 2015;170(1):118–122.
   PubMed Web of Science ®Google Scholar
• Combination chemotherapy with or without bortezomib in treating younger patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02112916
   Google Scholar
• Bortezomib and sorafenib tosylate in treating patients with newly diagnosed acute myeloid leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01371981
   Google Scholar
• Aplenc R. Personal communication. 2016 Apr 1.
   Google Scholar
• Roccaro AM, Vacca A, Ribatti D. Bortezomib in the treatment of cancer. Recent Pat Anticancer Drug Discov. 2006;1(3):397–403.
   PubMed Web of Science ®Google Scholar
• Blanco B, Perez-Simon JA, Sanchez-Abarca LI, et al. Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. Haematologica. 2009;94(7):975–983.
   PubMed Web of Science ®Google Scholar
• Cenci S, Mezghrani A, Cascio P, et al. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. Embo J. 2006;25:1104–1113.
   PubMed Web of Science ®Google Scholar
• Nencioni A, Garuti A, Schwarzenberg K, et al. Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol. 2006;36(3):681–689.
   PubMed Web of Science ®Google Scholar
• Moran E, Carbone F, Augusti V, et al. Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience. Semin Hematol. 2012;49(3):270–276.
   PubMed Web of Science ®Google Scholar
• Everly M, Everly J, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008;86(12): 1754–1761.
   PubMed Web of Science ®Google Scholar
• Flechner S, Fatica R, Askar M, et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation. 2010;90(12):1486–1492.
   PubMed Web of Science ®Google Scholar
• Waiser J, Budde K, Schutz M, et al. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant. 2012;27(3):1246–1251.
   PubMed Web of Science ®Google Scholar
• Desensitization with bortezomib before a living kidney donation. Available from: https://clinicaltrials.gov/ct2/show/NCT01842074
   Google Scholar
• Bortezomib in late antibody-mediated kidney transplant rejection. Available from: https://clinicaltrials.gov/ct2/show/NCT01873157
   Google Scholar
• Multi-drug desensitization protocol for heart transplant candidates. Available from: https://clinicaltrials.gov/ct2/show/NCT01556347
   Google Scholar
• El-Cheikh J, Michallet M, Nagler A, et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica. 2008;93(3):455–458.
   PubMed Web of Science ®Google Scholar
• Pai CC, Chen M, Mirsoian A, et al. Treatment of chronic graft-versus-host disease with bortezomib. Blood. 2014;124(10): 1677–1688.
   PubMed Web of Science ®Google Scholar
• Al-Homsi AS, Cole K, Bogema M, et al. Short course of post-transplantation cyclophosphamide and bortezomib for graft-versus-host disease prevention after allogeneic peripheral blood stem cell transplantation is feasible and yields favorable results: a phase I study. Biol Blood Marrow Transplant. 2015;21(7):1315–1320.
   PubMed Web of Science ®Google Scholar
• Koreth J, Kim HT, Lange PB, et al. A bortezomib-based regimen offers promising survival and graft-versus-host disease prophylaxis in myeloablative HLA-mismatched and unrelated donor transplantation: a phase II trial. Biol Blood Marrow Transplant. 2015;21(11): 1907–1913.
   PubMed Web of Science ®Google Scholar
• A study using tacrolimus, sirolimus and bortezomib as acute graft versus host disease (GVHD) prophylaxis in allogeneic peripheral blood stem cell (PBSC) transplantation. Available from: https://clinicaltrials.gov/ct2/show/NCT00670423
   Google Scholar
• Bortezomib for the treatment of refractory chronic graft-vs-host disease(cGVHD). Available from: https://clinicaltrials.gov/ct2/show/NCT01158105
   Google Scholar
• Bortezomib in patients with chronic graft versus host disease. Available from: https://clinicaltrials.gov/ct2/show/NCT01672229
   Google Scholar
• Carson KR, Beckwith LG, Mehta J. Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood. 2010;115(4):915.
   PubMed Web of Science ®Google Scholar
• Danchaivijitr P, Yared J, Rapoport AP. Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide. Am J Hematol. 2011;86(3):331–332.
   PubMed Web of Science ®Google Scholar
• Hosoba S, Jaye DL, Cohen C, et al. Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature. Transfusion. 2015;55(2):259–264.
   PubMed Web of Science ®Google Scholar
• Khandelwal P, Davies SM, Grimley MS, et al. Bortezomib for refractory autoimmunity in pediatrics. Biol Blood Marrow Transplant. 2014;20(10): 1654–1659.
   PubMedGoogle Scholar
• Sugumar D, Keller J, Vij R. Targeted treatments for multiple myeloma: specific role of carfilzomib. Pharmgenomics Pers Med. 2015;8:23–33.
   PubMed Web of Science ®Google Scholar
• Allegra A, Alonci A, Gerace D, et al. New orally active proteasome inhibitors in multiple myeloma. Leuk Res. 2014;38:1–9.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Tomaszewski JE. Proteasome inhibitors. Biochem Pharmacol. 2015;96:1–9.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.
   PubMed Web of Science ®Google Scholar
• Study of carfilzomib in combination with dexamethasone, mitoxantrone, PEG-asparaginase, and vincristine in children with relapsed or refractory acute lymphoblastic leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT02303821
   Google Scholar
• Offidani M, Corvatta L, Caraffa P, et al. An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma. Onco Targets Ther. 2014;7:1793–1800.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–1634.
   PubMed Web of Science ®Google Scholar
• Kyprolis [package insert]. Thousand Oaks (CA): Onyx Pharmaceuticals; 2012.
   Google Scholar
• Ninlaro [package insert]. Cambridge (MA): Millenium Pharmaceuticals; 2015.
   Google Scholar